Protagenic Therapeutics, Inc. (PTIX) Stock Overview
Explore Protagenic Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Protagenic Therapeutics, Inc. (PTIX)
Key Financials
Key Financials
Market Cap
724.1K
P/E Ratio
-0.15
EPS (TTM)
$-13.13
ROE
1.85%
PTIX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Protagenic Therapeutics, Inc. (PTIX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 38.77, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $2.57.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.15 and a market capitalization of 724.1K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.